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Gastric bypass surgery leads to marked improvements in glucose
tolerance and insulin sensitivity in obese type 2 diabetes (T2D);
the impact on glucose fluxes in response to a physiological
stimulus, such as a mixed meal test (MTT), has not been
determined. We administered an MTT to 12 obese T2D patients
and 15 obese nondiabetic (ND) subjects before and 1 year after
surgery (10 T2D and 11 ND) using the double-tracer technique
and modeling of b-cell function. In both groups postsurgery,
tracer-derived appearance of oral glucose was biphasic, a rapid
increase followed by a sharp drop, a pattern that was mirrored by
postprandial glucose levels and insulin secretion. In diabetic
patients, surgery lowered fasting and postprandial glucose levels,
peripheral insulin sensitivity increased in proportion to weight
loss (;30%), and b-cell glucose sensitivity doubled but did not
normalize (compared with 21 nonsurgical obese and lean con-
trols). Endogenous glucose production, however, was less sup-
pressed during the MMT as the combined result of a relative
hyperglucagonemia and the rapid fall in plasma glucose and in-
sulin levels. We conclude that in T2D, bypass surgery changes the
postprandial response to a dumping-like pattern and improves
glucose tolerance, b-cell function, and peripheral insulin sensitiv-
ity but worsens endogenous glucose output in response to a phys-
iological stimulus. Diabetes 62:3709–3717, 2013
Mounting evidence supports bariatric surgeryas a powerful intervention to induce re-mission in patients with type 2 diabetes (T2D)(1,2) and to prevent or delay incident T2D (3).
This has engendered enthusiasm for bariatric surgery as
a treatment for T2D (4) and has encouraged a broadening
of the BMI range as an indication for surgery in diabetic
patients (5).
Although weight loss and, in the early postoperative
period, caloric deficit certainly make a contribution to
improve glucose tolerance, surgery itself may trigger
weight-independent mechanisms eventually translating
into favorable metabolic effects. This postulate is based on
early animal studies (6) and, in humans, on evidence that
metabolic changes sometimes precede sizeable weight loss
or are disproportionate to the amount of weight lost (7). In
this regard, there is evidence that different bariatric proce-
dures (e.g., Roux-en-Y gastric bypass [RYGB], biliopancreatic
diversion, and sleeve gastrectomy) may engage putative
weight-independent mechanisms to different extents or in-
volve altogether different mechanisms (8,9).
A number of previous studies have documented the
effects of the most popular bariatric operation, RYGB, on
glycemic control and incretin hormones (10–24), and
mechanistic studies have explored the ability of RYGB to
enhance insulin action and b-cell function. The great ma-
jority of these studies have used methods based on fasting
measurements (e.g., homeostasis model assessments),
oral glucose tolerance test–based surrogate indices of
insulin sensitivity and b-cell function, or euglycemic-
hyperinsulinemic clamp settings (14,16–21). A recent study
(24) has taken a more physiological approach by com-
paring the impact of RYGB and gastric banding on the
disposition of a mixed meal, with the use of a double-
tracer technique, in nondiabetic (ND) subjects studied
before and shortly after the operation (;20 weeks). In the
current study of morbidly obese patients with T2D, we
aimed at measuring the impact of RYGB on chief physi-
ologic determinants of meal disposal long after surgery
(when body weight and metabolic adaptation have sta-
bilized) and assessing their relation to weight loss and the
attendant changes in the hormonal milieu.
RESEARCH DESIGN AND METHODS
Subjects. We studied 12 morbidly obese patients with T2D and 15 sex- and
BMI-matched morbidly obese ND patients. Diabetes was newly diagnosed in
three patients, whereas in the other nine patients, diabetes duration was 3.9 6
1.2 years (range 1–10). HbA1c was 7.2 6 0.4% (55 6 5 mmol/mol); six patients
were being treated by diet alone and six by oral hypoglycemic agents (three by
metformin alone and three by metformin plus a sulfonylurea). Antidiabetic
medication was discontinued 1 week before the metabolic studies. These 27
subjects all underwent laparoscopic RYGB; 10 T2D and 11 ND patients were
restudied 1 year after surgery. Two control groups were included, consisting
of 7 lean healthy volunteers and 14 obese ND volunteers whose BMI was
matched to that of the RYGB patients at 1 year postsurgery. Thus, a total of 69
complete metabolic studies were performed.
This study was approved by the local ethics committee. The nature and
purpose of the study were carefully explained to all participants before they
provided written consent to participate.
Study design. At baseline and follow-up, subjects received a mixed meal test
(MTT) with a double-tracer protocol. In brief, after an overnight (12-h) fast,
subjects were admitted to our Clinical Research Unit at 8:00 A.M., and a poly-
ethylene cannula was inserted into an antecubital vein for the infusion of all
test substances. A second catheter was inserted retrogradely into an ipsilateral
wrist vein on the dorsum of the hand for blood sampling, and the hand was
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kept in a heated box at 65°C to achieve arterialization of venous blood. Baseline
blood samples were drawn to measure plasma glucose, insulin, C-peptide,
glucagon, glucagon-like peptide 1 (GLP-1), and gastric inhibitory polypeptide
(GIP) concentrations and tracer enrichments. The MTT consisted of 75 g
glucose in 150 mL water, 40 g parmesan cheese, and one 50-g egg (509 kcal;
16% protein, 28% fat, and 56% carbohydrate). The glucose solution was drunk
after the solid component of the meal was consumed over a period of 10 min.
The oral glucose drink was enriched with 1-[2H]glucose in order to trace
glucose absorption. A primed (28 mmol $ kg21 3 [fasting plasma glucose]/5)
continuous (0.28 mmol $ min21 $ kg21) infusion of 6,6-[2H2]glucose was started
(at time –120 min, or at –180 min in the T2D patients) via the antecubital vein
catheter and continued until the end of the study. During the last 20 min of the
basal equilibration period (at times –20, –10, and 0 min), blood samples were
obtained for the determination of plasma glucose and hormone concentrations
and tracer enrichments (when isotopic steady state was achieved). After the
basal equilibration period, the meal was consumed over ;10 min. Plasma
samples for the determination of plasma glucose and hormone concentrations
and glucose tracer enrichments were obtained at 15, 30, 45, 60, 90, 120, 150, 180,
240, and 300 min after meal ingestion.
Surgical procedure. In subjects undergoing laparoscopic RYGB, a small
proximal gastric pouch of 30 mL was created with several firings of a linear
stapling endocutter; the jejunum was divided 120 cm distal to the ligament of
Treitz, and a 2-cm end-to-side gastrojejunostomy was performed by using
a hand-sewn technique. A side-to-side jejuno-jejunostomy was then created,
150 cm distal to the gastrojejunostomy (17).
Analytical procedures. Plasma glucose was measured by the glucose-oxidase
technique (Analox GM-9) and plasma insulin and C-peptide by electro-
chemiluminescence (on a COBAS e411 instrument; Roche, Indianapolis, IN).
Plasma triglycerides and serum HDL cholesterol were assayed in duplicate by
standard spectrophotometric methods on a Synchron Clinical System CX4
(Beckman Instruments, Fullerton, CA). 6,6-[2H2]glucose and 1-[
2H]glucose
enrichments were measured by gas chromatography–mass spectrometry as
described previously (25). Plasma glucagon was assayed by radioimmunoas-
say (Millipore Corporation, Billerica, MA). Plasma GLP-1 and GIP were
assayed by radioimmunoassay as described previously (26). No significant
cross-reactivity was declared by kit manufacturers. The sensitivity ranges are
0.003 nmol/L and 1.39 pmol/L for the C-peptide and insulin assay, respectively,
18.5 pg/mL for glucagon, and 1.5 pmol/L for GLP-1.
Data analysis. Fat-free mass was estimated with the use of electric bio-
impedance ona Tanita scale; of note, thismethod has been validated in very obese
individuals against the deuterated water technique (27). Endogenous glucose
production (EGP) in the fasting state and throughout the absorptive period and
rate of appearance of the oral glucose component (RaO) of the meal were cal-
culated from the time course of the plasma tracer/tracee ratio of 6,6-[2H2]glucose
and 1-[2H]glucose by two-compartment modeling, as previously described (25).
Insulin sensitivity was calculated as the mean metabolic clearance rate of glu-
cose (MCRG) during the 5 h of the MTT (from 6,6-[
2H2]glucose kinetics) divided
by the mean plasma insulin concentration over the same time interval.
b-Cell function was quantitated by mathematical modeling of the plasma
C-peptide response, as previously described (28). In brief, the model consists
of three blocks: 1) a model for fitting the glucose concentration profile, the
purpose of which is to smooth and interpolate plasma glucose concentrations;
2) a model describing the dependence of insulin (or C-peptide) secretion on
glucose concentration; and 3) a model of C-peptide kinetics, i.e., the two-
exponential model proposed by Van Cauter et al. (29), in which the model
parameters are individually adjusted to the subject’s anthropometric data. The
main parameter of the model is b-cell glucose sensitivity (b-GS), which is
calculated as the mean slope of the dose-response function (i.e., relationship
between insulin secretion rates [ISRs] and plasma glucose concentrations
during corresponding times of the MTT). The model also yields an estimate of
glucose rate sensitivity, which is the insulin secretory response to the rate of
change in plasma glucose concentrations, and total insulin output, which is the
total amount of insulin released over the 5 h of the meal (28). Plasma insulin
clearance (MCRI) was estimated as the ratio of fasting ISR to the fasting
plasma insulin concentration.
The prehepatic insulin-to-glucagon molar concentration ratio was estimated
by the following formula: {ISR[t]/hPF + [I(t)]}/{[Glg(t)] 3 [1 + MCRGlg/hPF]},
where ISR(t) is the ISR at time t, hPF is hepatic plasma flow, [I(t)] and [Glg(t)]
are the measured peripheral plasma concentrations of insulin and glucagon
at time t, and MCRGlg is the metabolic clearance rate of glucagon. hPF was
estimated by multiplying the cardiac index (3.2 L $ min–1 $ m22) (30) by a
plasma-to-blood ratio of 0.6, and by assuming that hepatic blood flow is
30% of cardiac index (=0.576 L $ min21 $ m22) (31). MCRGlg was taken to be
0.537 L $ min21 $ m22 (32).
The product of mean EGP and mean plasma insulin levels during the meal
was taken as an index of hepatic insulin resistance. Areas under time-
concentration curves (AUCs) were calculated by the trapezium rule.
Statistical analysis. All data are given as the mean 6 SEM; parameters that
were nonnormally distributed are presented as the median (interquartile range).
Mann-Whitney test was used to compare group values, whereas surgery-induced
changes were tested by the Wilcoxon signed rank test. Time series were ana-
lyzed by ANOVA for repeated measures; for these tests, variables with skewed
distribution were log transformed. Group differences over time series were
analyzed by two-way ANOVA for repeated measures. Simple associations were
tested by calculating the Spearman rank correlation coefficient (r). Statistical
analyses were performed using JMP7.0 and StatView5.0. P # 0.05 was consid-
ered statistically significant.
RESULTS
Baseline. The four subject groups were matched for sex
and age; T2D patients were older and had moderate fasting
hyperglycemia (Table 1). After meal ingestion, plasma
glucose excursions were similar in lean and obese controls
and ND surgical patients, whereas T2D patients showed
marked hyperglycemia (Fig. 1A). Fasting and postprandial
insulin concentrations were higher in all three obese
groups than in lean controls (Fig. 1B and Table 2). Fasting
ISR generally increased with obesity as did the total insulin
output over the 5 h of the test (Fig. 1C and Table 2). In T2D
TABLE 1
Anthropometric and metabolic parameters
ND T2D
Lean cts Obese cts Presurgery P 1 year Presurgery P 1 year
n 7 15 11 11 10 10
HbA1c (%) — — — — — 7.1 6 0.5 0.008 5.4 6 0.1
Body weight (kg) 63 6 2 94 6 4§ 146 6 6§* 0.003 99 6 5§ 139 6 9§* 0.005 91 6 6§
Weight change (kg) — — — — 246.0 6 5.2 — — 248.1 6 3.3
Weight change (%) — — — — 231.3 6 2.9 — — 234.6 6 1.1
BMI (kg $ m22) 23 6 1 34 6 1§ 52.8 6 1.8§* 0.003 36.1 6 1.6§ 51.6 6 2.6§* 0.005 33.7 6 1.8§
Fat-free mass (kg) 44 6 1 54 6 2§ 70.0 6 3.6§* 0.003 58.3 6 3.2§ 75.2 6 6.4§* 0.009 61.4 6 3.7§
Fat mass (kg) 19 6 2 40 6 3§ 75.8 6 3.9§* 0.003 41.0 6 3.5§ 64.2 6 6.3§*# 0.005 29.9 6 4.1
Fat mass (%) 29 6 2 42 6 2§ 52.3 6 1.6§* 0.003 40.9 6 2.0§ 45.9 6 2.9§* 0.005 31.8 6 3.1*#
Fasting [G] (mmol/L) 5.2 6 0.2 5.3 6 0.1 5.47 6 0.13 0.02 5.05 6 0.13 8.79 6 0.87§*# 0.005 4.97 6 0.16
Fasting [I] (pmol/L) 54 (28) 81 (38)§ 143 (40)§* 0.003 44 (18)* 163 (145)§ 0.005 60 (25)*
Fasting C-peptide (nmol/L) 0.46 (0.40) 0.52 (0.24) 1.41 (0.61)§* 0.003 0.48 (0.18) 0.88 (0.54)§* 0.01 0.54 (0.24)
All data are given as the mean 6 SEM; parameters that were nonnormally distributed are presented as the median (interquartile range).
G, glucose; I, insulin; Lean cts, lean controls; Obese cts, obese controls. P vs. presurgery by Wilcoxon test. *P # 0.05, vs. obese controls. §P #
0.05, vs. lean controls by Mann-Whitney U test. #P # 0.05, ND vs. T2D pre or 1 year.
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patients, total insulin output was not different from that of
lean controls despite the hyperglycemia. Consequently,
b-GS was markedly impaired in this group (Fig. 1D and
Table 2).
On the MTT, the RaO was similar in all groups, both in
time course (Fig. 1E) and amount (averaging 51, 52, 50, and
62 g over 5 h in lean control subjects, obese control sub-
jects, ND surgical patients, and T2D surgical patients, re-
spectively) (Table 2). In contrast, fasting EGP was higher
in each obese group (700 [277], 771 [242], and 764 [395]
mmol/min) than in lean controls (580 [51] mmol $ min21)
and remained higher during the MTT despite the postmeal
hyperinsulinemia (AUCEGP = 79 [46], 100 [56], and 100 [97]
mmol vs. 61 [15] of controls). The difference in EGP time
course between each of the obese groups and lean controls
(confirmed by repeated-measures ANOVA, P, 0.001 for all)
was evident after the initial nadir (Fig. 1F). In the whole
dataset, both fasting EGP and AUCEGP were positively re-
lated to BMI (r = 0.48, P = 0.001, and r = 0.30, P = 0.05,
respectively). Plasma glucose clearance rose during the
MTT in all groups; its mean value over 5 h was reduced in
both surgical groups, especially in T2D patients, in com-
parison with lean controls despite the hyperinsulinemia
(Table 2). As a consequence, insulin sensitivity, as the
insulin-mediated MCRG, was lower in both obese groups
and severely impaired in T2D patients (Table 2).
In all obese groups, fasting plasma glucagon was in-
creased, whereas the meal-induced glucagon increments
were blunted. Fasting GLP-1 and GIP levels were in-
creased only in T2D patients, as was AUCGIP (Table 2).
FIG. 1. Plasma glucose (A) and insulin concentrations (B), ISRs (C), and insulin secretion dose response (D), RaO (E), and EGP (F) in the four
groups of study subjects at baseline. The gray shaded areas are the mean 6 SEM for the lean control group, and the green shaded area is the
mean 6 SEM for the obese control group. Pts, patients.
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After surgery. At 1 year, ND and T2D patients had lost 31
and 35% of their initial body weight, respectively, in an
approximate ratio of 1:3 between fat-free mass and fat
mass (Table 1). In T2D patients, HbA1c had dropped by an
average 1.5%, and all patients were off antidiabetic drug
treatment; of them, two patients had impaired glucose
tolerance and one of these two also had impaired fasting
glucose (5.9 mmol/L). Four patients experienced dumping-
like symptoms (tachycardia, sweating, nausea, and di-
arrhea) after meal ingestion.
On the MTT, the postsurgery plasma glucose and insulin
profiles were grossly altered in both ND and T2D subjects,
with a large excursion peaking at 60 min followed by
a sharp drop to basal levels or below (Fig. 2). In the T2D
group, the glucose and insulin AUCs were significantly
smaller than preoperatively (Table 2). The time course of
insulin secretion ran parallel to that of plasma glucose
(Fig. 3); fasting insulin secretion decreased in both groups
and total insulin output decreased in the ND group (Table
2). When viewing insulin secretion in the context of the
corresponding plasma glucose levels, b-GS was signifi-
cantly reduced in the ND group postsurgery (although still
within the range of the obese control group), and ;100%
increased in T2D patients (although still largely below
control values) (Fig. 3). The small decline in b-GS in ND
subjects could be due to chronically reduced carbohydrate
intake or could simply be time related. Insulin sensitivity
improved significantly in both groups (by two-way ANOVA
from repeated measures, F = 10.5, P , 0.005) to levels
similar to those of the obese controls. The estimates of
insulin sensitivity fell along the overall relationship de-
scribing the association of insulin resistance with BMI, and
the surgically induced changes in insulin sensitivity were
correlated with the corresponding changes in body weight
(Table 2 and Fig. 4).
In both ND and T2D subjects postsurgery, the rate of
appearance of oral glucose was similar in total amount
(Table 2) but distorted in time course, in a manner re-
sembling the plasma glucose curves closely (Fig. 5). Thus,
most oral glucose was absorbed during the first hour after
meal ingestion, as the AUC calculated in the first 60 min
showed (AUC pre- vs. postsurgery: 122 [63] vs. 186 [37]
mmol in ND and 129 [81] vs. 190 [94] mmol in T2D, P, 0.04
vs. postsurgery for both). EGP was unchanged in ND as
well as T2D patients in the fasting state but rebounded
significantly above presurgery values during meal absorp-
tion, particularly over the second half of the postcibal pe-
riod when plasma glucose concentrations were back to
basal or below. The EGP time course was increased in both
groups (with no significant difference between T2D and ND
patients, P = 0.74), whether expressed in absolute terms
(Fig. 5) or normalized by fat-free mass (F = 133.9, P ,
0.0001) (Table 2).
Fasting glucagon levels dropped in both ND and T2D, but
the response to the meal (as the incremental AUC) was
greatly enhanced in both groups (Table 2 and Fig. 6). After
surgery, the estimated prehepatic insulin-to-glucagon molar
concentration ratio was higher than presurgery (especially
TABLE 2
Glucose metabolism and insulin secretion
ND T2D
Lean cts Obese cts Presurgery P 1 year Presurgery P 1 year
Mean glucose [G] (mmol/L) 6.1 6 0.2 6.1 6 0.1 6.0 6 0.2 NS 5.9 6 0.1 9.3 6 0.9*# 0.005 6.4 6 0.3
AUCG (mol/L) 1.80 (0.17) 1.84 (0.21) 1.76 (0.26) NS 1.79 (0.17) 2.58 (0.99)§*# 0.01 1.87 (0.19)
Mean insulin [I] (pmol/L) 181 (81) 353 (208)§ 493 (269)§ NS 416 (274)§ 353 (581)§ 0.02 320 (247)
AUCI (nmol) 56 (15) 92 (65)§ 148 (81)§ NS 125 (82)§ 106 (113)§ 0.03 96 (60)
Mean C-peptide (nmol/L) 1.59 (0.71) 1.41 (1.10) 2.90 (1.03)§* 0.02 1.80 (0.71) 1.85 (1.23) NS 1.74 (0.91)
AUCC-pep (mmol) 0.48 (0.21) 0.42 (0.33) 0.87 (0.31)§* 0.01 0.54 (0.21) 0.56 (0.37)* NS 0.52 (0.27)
Fasting ISR (pmol $ min21 $ m22) 54 (28) 74 (25) 147 (69)§* 0.004 57 (28) 104 (62) 0.02 73 (35)
IS (nmol $ m22) 64 (23) 59 (37) 100 (29)§* 0.03 68 (30) 66 (28)# NS 65 (44)
MCRI (L $ min
21 $ m22) 1.66 (1.25) 0.95 (0.32)§ 1.17 (0.73) NS 1.50 (0.67)* 1.00 (0.73) 0.02 1.37 (0.26)*
b-GS (pmol $ min-1 $ m22 $ mM21) 96 (60) 110 (92) 122 (41) 0.02 91 (19) 33 (25)§*# 0.007 61 (38)§*#
Rate sensitivity (nmol $ m22) 4.3 (3.0) 4.1 (5.0) 5.2 (4.9) 0.04 15.0 (13.3) 2.6 (3.2)§*# 0.01 10.9 (8.4)*
Fasting EGP
(mmol $ kgFFM
21 $ min21) 13.3 (1.7) 13.1 (4.0) 12.1 (0.4) NS 11.9 (0.6) 11.9 (0.9) NS 13.3 (0.8)
AUCEGP (mmol $ kgFFM
21) 1.41 (0.22) 1.39 (0.87) 1.57 (0.80) 0.008 2.18 (0.89)§* 1.36 (1.39) (0.09) 2.04 (1.15)§
AUCRaO (mmol) 283 (79) 290 (28) 288 (59) NS 264 (52) 343 (81) NS 332 (242)
MCRG (mL $ min
21 $ kgFFM
21) 4.4 (1.1) 4.2 (0.4) 3.6 (1.1)§* NS 3.6 (0.9) 2.3 (0.8)§*# ,0.01 3.4 (1.2)
MCRG/[I] (mL $ min
21 $
kgFFM
21 $ nM21) 24.4 (8.4) 10.5 (12.0)§ 7.6 (5.2)§ NS 9.1 (9.2)§ 6.7 (3.6)§* 0.008 11.3 (9.2)§
Fasting glucagon (pg $ mL21) 38 (17) 69 (33)§ 69 (40)§ 0.006 50 (23)* 69 (49)# 0.03 32 (16)*
AUCGlucagon (ng $ mL
21) 17.1 (4.4) 22.1 (6.2)§ 24.6 (7.8) NS 49.7 (25.7)§ 23.2 (17.5) NS 29.1 (21.9)
∂AUCGlucagon (ng $ mL21) 2.8 (3.7) 0.6 (3.9)§ 0.6 (7.4)§ 0.006 10.5 (8.4)§* 0.3 (3.0)§ 0.007 5.7 (4.5)*
Fasting GIP (pmol/L) 4.5 (5.5) 10.0 (7.0) 9.0 (12.5) NS 7.0 (4.0) 11.5 (10.0)§ NS 9.5 (11.0)
AUCGIP (nmol $ L
21) 12.5 (11.1) 7.2 (3.6) 6.6 (3.6) NS 6.7 (3.3)§ 11.3 (7.5)*# NS 8.0 (9.8)
∂AUCGIP (nmol $ L21) 11.9 (12.3) 3.6 (4.4)§ 4.1 (3.1) NS 4.5 (3.2) 8.3 (7.2) NS 5.7 (6.0)
Fasting GLP-1 (pmol/L) 11.0 (12.0) 7.0 (4.5) 9.0 (7.0) NS 11.0 (7.0)* 12.5 (12.0)*# NS 11.5 (7.0)*
AUCGLP-1 (nmol $ L
21) 6.3 (3.0) 4.5 (2.2) 6.2 (3.6) 0.008 16.8 (9.3)§* 4.7 (3.7) 0.02 12.1 (18.5)*
All data are given as the mean 6 SEM; parameters that were nonnormally distributed are presented as the median (interquartile range). AUC,
area under the curve; b-GS, b-cell glucose sensitivity; EGP, endogenous glucose production; ISR, insulin secretion rate; ∂AUC, incremental
AUC; IS, total insulin output; Lean cts, lean controls; MCRG, metabolic clearance rate of glucose; MCRI, insulin clearance; Obese cts, obese
controls; RaO, rate of appearance of oral glucose. P vs. presurgery by Wilcoxon test. *P # 0.05, vs. obese controls. §P# 0.05, vs. lean controls
by Mann-Whitney test. #P # 0.05, ND vs. T2D pre or 1 year. The P value in parentheses shows that it is near the statistical significance.
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in T2D patients) for the first 80–100 min but then fell below
preoperative levels for the remainder of the MTT in both
groups (Supplementary Fig. 1).
The GLP-1, but not the GIP, response was increased in
ND as well as T2D; the time profile of the GLP-1 and GIP
responses showed a sharper early rise and a rapid drop
thereafter (Fig. 6).
MCRI, calculated as the ratio of fasting insulin output to
fasting peripheral plasma insulin concentrations, was
slightly reduced in the obese groups as compared with the
lean controls and was significantly increased postsurgery
in both ND and T2D (two-way ANOVA).
DISCUSSION
Before the operation, the metabolic response to the mixed
meal in the ND obese subjects was characterized by insulin
resistance of glucose disposal and insulin hypersecretion,
with preserved b-GS and rate sensitivity, i.e., the metabolic
picture of obesity. In the T2D patients, insulin resistance
was worse, and both b-GS and rate sensitivity were mark-
edly impaired, thereby accounting for the hyperglycemia.
Whereas the rate of appearance of oral glucose was similar
in time course and total amount in all groups, in obese and
T2D patients, EGP was higher at baseline and was in-
completely suppressed during the meal, in some proportion
to the degree of obesity, despite the hyperinsulinemia,
thereby manifesting liver insulin resistance. In the T2D pa-
tients, the blunted rise in the prehepatic insulin-to-glucagon
ratio during the first 2 h postmeal (Supplementary Fig. 1)
likely contributed to the elevated EGP.
One year after RYGB, at a time when drastic weight loss
had occurred and body weight had stabilized, fasting
plasma glucose was similar in ND and diabetic patients, but
in the latter, 2-h glucose concentrations were significantly
higher (5.93 6 0.53 vs. 4.23 6 0.31 mmol/L, P = 0.02), and
mean glucose levels during the 5-h meal tended to be higher
(Table 2), than in ND surgical patients. Insulin sensitivity
improved in both surgical groups to levels close to those of
the BMI-matched control group, i.e., in rough proportion to
the weight loss and without reaching the values of the lean
control subjects (Fig. 4). This result, obtained by tracer
analysis of a dynamic test such as the MTT, confirms the
findings of steady-state (clamp) measurements of insulin
sensitivity (17), namely, that RYGB does not potentiate in-
sulin action beyond, or independenty of, the effect on
weight loss. b-GS worsened slightly in the ND surgical
patients, whereas it doubled in the diabetic patients, in
whom, however, it remained markedly inferior to that of
BMI-matched ND subjects. This outcome prevailed despite
the large increase in GLP-1 response, a consistent change
after bariatric surgery (10–17), even as long as 10 years after
surgery (33), which is quantitatively related to enhanced
insulin secretion (19). In both groups, rate sensitivity im-
proved postsurgery, likely reflecting the rapid plasma glu-
cose excursions as well as, at least in part, the heightened
GLP-1 surge (Supplementary Fig. 2A). The latter finding is
compatible with evidence that a rapid rather than delayed
delivery of insulin improves glucose tolerance irrespective
of the degree of insulin resistance (34), and may explain
why meal tolerance in our patients was preserved 1 year
after surgery despite the abnormal b-GS.
FIG. 2. Plasma glucose and insulin concentrations in the patients (pts) before and after RYGB. The corresponding data for the obese control group
are shown by the gray line.
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Thus, in T2D patients, recovery of both insulin sensi-
tivity and glucose sensitivity was sizeable but incomplete,
leaving behind a trace of glucose intolerance. These
results confirm previous findings in both ND and T2D
subjects, using a liquid formula meal and homeostasis
model assessment of insulin resistance as a surrogate in-
dex of insulin resistance (35), or an oral glucose tolerance
test (18). Further increments in both functions may occur
if more weight is lost or as removal of the toxic effects of
hyperglycemia continues; on the other hand, diabetes may
relapse if weight is regained, if insulin resistance otherwise
worsens, or if the disease itself should progress. In addi-
tion, as previously shown, in T2D patients, the outcome of
glucose tolerance at 1 year post-RYGB may be better or
worse than in the present series of patients depending on
the initial degree of b-cell dysfunction (18).
As found by Bradley et al. (24) in ND subjects, RYGB
drastically changed the shape of the glucose and hormonal
responses to the meal, with a markedly biphasic pattern
reminiscent of a dumping syndrome. Glucose fluxes con-
firmed that this was the consequence of the altered de-
livery of gastric contents to the peripheral circulation. A
somewhat unexpected consequence of the altered pattern
of transit of alimentary glucose was the reduced suppres-
sion of endogenous glucose release during the meal. Under
euglycemic clamp conditions, hepatic and peripheral in-
sulin resistance are typically somewhat interrelated and
change consensually (36). A mixed meal, however, creates
a hormonal makeover by stimulating both insulin and
glucagon secretion, especially in diabetic patients in whom
glucagon responses are exaggerated (37). In our surgical
patients, both fasting insulin and fasting glucagon con-
centrations fell significantly postsurgery; correspondingly,
fasting EGP did not change after the operation. After the
meal, the prehepatic insulin-to-glucagon molar ratio nor-
mally rises in a time course roughly parallel to that of
FIG. 3. ISR and dose-response function in the patients (pts) before and after RYGB. The corresponding data for the obese control group are shown
by the shaded areas.
FIG. 4. Insulin sensitivity (as the ratio of mean glucose clearance to
mean insulin concentration during a 5-h MTT) plotted against the
corresponding BMI value in the four study groups. The points to the far
right are those for the surgical groups before the operation. Plots are
median (interquartile range). The dotted line is a power function fit of
the plots. The inset shows the relationship between the change in in-
sulin sensitivity and the percent change in body weight in the surgical
patients (pts); the linear fit and the 95% CI are shown.
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plasma glucose concentrations and ISRs; in T2D patients,
the ratio shows the blunted initial rise followed by a sus-
tained increase typical of the insulin secretory response
(Supplementary Fig. 1). After surgery, however, plasma
glucagon rose sharply and remained above basal levels
throughout the absorption period both in ND and T2D
patients (Fig. 6), such that the prehepatic insulin-to-
glucagon ratio, after peaking at ;1 h postmeal, dropped
rapidly to levels below presurgery (Supplementary Fig. 1),
in phase with the lower plasma glucose levels. Thus, the
raised postmeal EGP was the integrated liver response to
lower insulin, higher glucagon, and falling glucose levels.
The correlation between the calculated index of hepatic
insulin resistance and the glucagon response supports the
role of the relative hyperglucagonemia (Supplementary
Fig. 2B). It should be noted that in the cited study in ND
subjects (24), the time course of EGP was similar to ours
but the glucagon response was rather flat and unchanged
from presurgery. This difference may be due to the use of
a smaller meal (;300 kcal with only 9 g of protein com-
pared with 500 kcal in the current study) and/or the
shorter time interval from surgery (22 weeks), a time at
which patients are typically still losing weight. The stim-
ulus for the meal-induced hyperglucagonemia 1 year after
surgery, which has been noted before (15), remains un-
determined. Diminished paracrine control of a-cell activity
by insulin (38) seems unlikely as the glucagon excursions
in our patients were essentially synchronous with those of
plasma insulin. Potential mechanisms are enhanced post-
prandial neural stimulation (39), overstimulation of gluca-
gon release by GIP (40) or GLP-2 (41), and cosecretion of
glucagon and GLP-1/GIP by intestinal cells (42). In our data,
the postsurgery time courses of glucagon and GIP were in
phase, lending some support to an effect of GIP on a-cells. It
FIG. 5. Rate of appearance of oral glucose (RaO), endogenous glucose (EGP), and glucose clearance rate in the patients (pts) before and after
RYGB. The corresponding data for the obese control group are shown by the shaded areas. By two-way ANOVA, the time course of EGP is sig-
nificantly higher postsurgery than presurgery (F = 27.6, P < 0.0001) in both ND and T2D.
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should also be considered that the standard glucagon
assay has limitations in terms of its ability to discriminate
between pancreatic glucagon and other sources (43).
Although gastric emptying was not measured in the
present studies, our previous work in post-RYGB patients
(using a scintigraphic technique) has confirmed that the
operation causes accelerated gastric emptying even 14–26
months later (44); this result is fully compatible with the
accelerated appearance of oral glucose in the present series.
In summary, the long-term outcome of RYGB is a com-
parable weight reduction and a proportional improvement in
insulin sensitivity in ND and well-controlled, recent-onset
diabetic patients. In both, delivery of oral glucose to the
peripheral circulation is maintained in quantity but strikingly
changed in time course, with a “dumping” pattern resulting
from the modified anatomy. Glucose tolerance is preserved
in ND and much improved in diabetic patients; in the latter,
a detectable degree of glucose intolerance persists. In di-
abetic patients, b-cell function improves presumably as a
combined result of reversal of glucose toxicity, lower
insulin secretory burden, and incretin-mediated potentia-
tion, but b-GS remains subnormal. This may predispose
patients to recurrent diabetes. The surgery-induced change
in glucose delivery triggers not only a heightened GLP-1
response but also an exaggerated glucagon response syn-
chronous with the glucose excursions, which likely con-
tributes to maintain euglycemia through elevated rates of
EGP.
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